NAVPNational Association of Vision Professionals
NAVPNew Age Video Productions (Humble, TX)
NAVPNational Association of Veterinary Physiotherapists (UK)
Copyright 1988-2018, All rights reserved.
References in periodicals archive ?
The antiepileptic drug NaVP has the promising anticancer effects: it stimulates histone acetylation, leading to an unfolding of the chromatin structure that leaves DNA more susceptible to the effects of chemotherapy and radiation therapy [44].
The majority of tumors which developed from U87 cells without NaVP treatment during tumor growth destroyed the chorionic epithelium and invaded the mesenchyme.
The treatment of U87 cells with 8 mM of NaVP did not show clear dynamics of tumor growth during 5 days of development at EDD9-12; at the same time, the blood vessel angiogenesis failed.
The studied GBM U87 cell tumor samples showed a strong nuclear staining of EZH2 in U87 cell tumors without NaVP treatment, and a high expression of the EZH2 protein in the tumor cell nuclei was found.
In our study, the expression of EZH2 protein was observed also in the chorionic and allantoic epithelium and CAM mesenchyme in nontreated with NaVP tumors.
We found that the number of EZH2-positive cells was significantly lower in tumors treated with 4 mM and 8 mM of NaVP as compared with the cell count in nontreated tumors, and the NaVP effect was higher as its concentration increased to 8 mM.
The study shows that, in tumors formed by the U87 cells without NaVP treatment, a high expression of the p53 protein was found.
Our study revealed a high expression of p53 in U87 cell tumors which were not treated with NaVP, and this expression was accompanied with pronounced angiogenesis in tumors in the CAM model.
In our U78 tumors on CAM treated with NaVP, the number of p53-positive cells significantly diminished, and only a significantly decreased number of p53-positive cells in tumors treated with 8 mM of NaVP were observed.
The experimental findings of the study indicate that NaVP has a function in blocking the proliferation, migration, and angiogenesis of human U87 gliomacells in the CAM tumor model, there by supporting the NaVP potential in glioblastoma therapy.
Figure 1 represents the U87 cell tumor xenografts on CAM growth dynamics, which was photographed daily on days 9-12 of embryo development (EDD9-12): (a) represents nontreated tumors, (b) NaVP-treated (with 4 mM of NaVP) tumors, and (c) NaVP-treated (with 8 mM of NaVP) tumors.
(c) Membrane with tumor developed from U87 cells treated with 4mM NaVP. The dotted arrow shows the destroyed chorionic epithelium and partial tumor invasion into the mesenchyme.